Pure Global
NCT03392324

PRIMA US-Feasibility Study in Atrophic Dry AMD

Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Pixium Vision SA·ClinicalTrials.gov·device·Device trialActive, not recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
PRIMA
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Pixium Vision SA
Location
Palo Alto,Miami,Pittsburgh, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 26, 2018
End date
Dec 01, 2025
Enrollment
5 participants
Primary outcome

Near Visual Acuity

Summary

In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA
 is tested in five subjects suffering from atrophic dry age related macular degeneration.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03392324
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT03392324 through Pure Global AI's free database. This phase not specified trial is sponsored by Pixium Vision SA and is currently Active, not recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 5 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.